Mylan Appoints Adele Gulfo as EVP, Global Collaboration and Strategic Operations
PITTSBURGH, Jan. 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the appointment of Adele Gulfo as executive vice president, Global Collaboration and Strategic Operations. Gulfo will serve as a member of Mylan's executive leadership team.
Prior to joining Mylan, Gulfo served as regional president of Latin America in Pfizer's Emerging Markets Business Unit. In this capacity, she led a team of over 4,000 colleagues operating across more than 23 countries. In 2012, under her leadership, the Latin American business achieved more than $3 billion in revenue, making it the largest revenue generator within the Business Unit. Previously, Gulfo served as president and general manager of Pfizer's U.S. Primary Care Business Unit, which included the Managed Markets (Corporate and Government Customer) organization for all of Pfizer's Biopharmaceutical Business Units. In 2011, Pfizer's U.S. Primary Care business generated $13 billion in revenue under her leadership. Earlier in her career at Pfizer, Gulfo was instrumental in the launch of LIPITOR®, which became the world's most successful medicine in terms of sales, and was recognized for developing medical and public education campaigns that helped to establish the significance of lowering cholesterol in preventing and managing heart disease.
Mylan CEO Heather Bresch commented, "Adele's rich and diverse experience in the pharmaceutical industry will bring significant strategic value and leadership to Mylan in numerous areas. For instance, we believe Adele's expertise will support many of our key growth drivers, including our expansion in Latin America, the development and expansion of our global Specialty franchise, and the development of global commercial strategies to maximize our key upcoming launches of increasingly complex generic products, such as in the biologics and respiratory areas. Further, Adele has proven her ability to drive collaboration across and among large, complex organizations in order to leverage capabilities and best practices to drive revenue, and we believe she can support our continued efforts to differentiate Mylan's comprehensive commercial offering to our customers."
Gulfo said, "I had the privilege of collaborating with Mylan during my time at Pfizer, and I am energized both by Mylan's mission to provide high quality medicine to the world's population and by the significant opportunities for growth I see ahead for the company. Mylan brings customers and patients a unique value proposition in terms of its broad product portfolio, vertically-integrated high quality manufacturing platform and expansive global commercial reach. The company's initiatives to leverage these strengths and build on them, for instance through the addition of differentiated products and enhanced services, will further distinguish Mylan from its peers. I look forward to utilizing my expertise and relationships to help execute on this strategy and support Mylan's transformation from a pharmaceutical company into a health care company."
Prior to joining Pfizer, Gulfo was vice president of Business Development, Innovation and Design for Launch at Astra-Zeneca Pharmaceuticals. In her nine years with the company, she led the multi-billion dollar cardiovascular business, including marketed and emerging products. Among other achievements, she grew Toprol-XL® sales from $200 million to $2 billion and launched cholesterol-lowering medicine Crestor® with a significantly differentiated life-cycle development program, growing it to a more than $2 billion product in 2009.
Gulfo has been awarded five U.S. patents for innovative packaging designed to help patients adhere to their medicines. She holds a bachelor's degree in Biology from Seton Hall University and a MBA from Fairleigh Dickinson University. She also studied post-graduate microbiology and began her career at the University of Medicine and Dentistry of New Jersey.
This press release includes statements that constitute "forward-looking statements," including with regard to the company's future growth and performance. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; the ability to attract and retain key personnel; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.